Enrolling by invitationPhase 2
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
Key facts
- Who runs it
- Alterity Therapeutics
- Where
- France4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- Phase
- Phase 2
- People taking part
- 7 people, planned
- Started
- 1 Oct 2026
- Expected to end
- Jul 2029
- Type of study
- Interventional
- Treatments tested
- ATH434
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Completed Alterity protocol ATH434-201
- Expected to benefit from treatment from treatment with ATH434, in the opinion of the Investigator
Who cannot take part
- Discontinued prior ATH434 treatment (ATH434-201) for any reason
- Significant medical or psychiatric condition that may decrease the benefit-risk ratio of participation in this program to an unacceptable level, as per the Investigator's opinion
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
The group in the trial
- ATH434 75mg BIDTreatment being tested
Participants who completed the prior ATH434-201 Phase 2 trial will receive ATH434 75 mg orally twice daily (BID). Treatment consists of an initial 12-month treatment phase, followed by an ongoing extension phase based on investigator assessment of continued clinical benefit, safety, and tolerability
Treatment: ATH434
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Open-Label Extension Study to Provide Access to ATH434 in Patients With Multiple System Atrophy
- Record updated
- 9 October 2026